Landos Biopharma Inc expected to post a loss of 31  cents a share - Earnings Preview

Landos Biopharma

13/05/2022 12:43

* Landos Biopharma Inc  LABP.OQ   LABP.O  is expected
to show a
fall in quarterly revenue when it reports  results on July 27
(estimated). 
    * ​Refinitiv's mean analyst estimate for Landos Biopharma
Inc is
for a loss of 31 cents per share. For the same quarter last
year, the company reported earnings of 12 cents per share.
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 5.1%
in the last three months. ​
    * Wall Street's median 12-month price target for Landos
Biopharma
Inc is $16​, above​ its last closing price of $0.67. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2022  -0.31       -0.35                        
 Dec. 31 2022              -0.33                        
 Sep. 30 2021  -0.44       -0.44      -0.32     Beat    27​
 Jun. 30 2021  0.04        -0.14      0.12      Beat    185.7
 ​​Mar.        -0.39       -0.37      -0.38     Missed  -1.3
 31 2021                                                
 Dec. 31 2020  -0.69       -0.69      -0.91     Missed  -32.5​
 This summary was machine generated May 13 at 11:43 GMT.  All
figures in US dollars  unless otherwise stated